Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.
Sandor Schoichet
Advertisement
Articles by Sandor Schoichet
Meaningful biopharma sustainability metrics are a crucial challenge.
Biopharma sustainability resolutions for a better 2021.
Why major companies are stepping up environmental commitments.
SynBio opens new environmental sustainability possibilities for pharma.
Biopharma must find sustainable models for public policy engagement.
ESG objectives are integral to long-term biopharma strategy.
The need for clear transparency around use of real-world data, AI.
Advertisement
Latest Updated Articles
Why ESG Performance Metrics MatterMarch 11th 2021
Pharma’s Digital-Trust MandateAugust 7th 2020
The Regulatory Engagement ConundrumOctober 14th 2020
A New Year for Sustainable GovernanceJanuary 13th 2021
- Sustainable Long-Term Planning
September 11th 2020
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
What is the Next Threat Manufacturers at Access USA Need to Be Preparing For?
5